Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
01:45am, Sunday, 11'th Feb 2024
PTC Therapeutics could soon lose one of its major products in the E.U. Sarepta Therapeutics competes in the same disease market as PTC.
PepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 data
06:06am, Tuesday, 06'th Feb 2024
PepGen Inc. NASDAQ: PEPG is a clinical-stage biotech focused on developing therapies for rare neuromuscular and neurological genetic diseases like Duchenne muscular dystrophy (DMD). PepGen utilizes it
Sarepta says its experimental Duchenne drug more effective than older medicine
07:17am, Monday, 29'th Jan 2024
Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a mus
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
09:45am, Thursday, 25'th Jan 2024
Sarepta Therapeutics and Vertex Pharmaceuticals both go after rare diseases. Sarepta has made headway in its core area, but there is more work to be done.
Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations
04:31am, Wednesday, 24'th Jan 2024
Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapy and RNA-targeted treatments for rare diseases such as Duchenne muscular dystrophy and Limb-girdle muscular dystro
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
07:21am, Tuesday, 23'rd Jan 2024
Sarepta Therapeutics Inc. NASDAQ: SRPT is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. This medical sector company specializes in
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
05:47pm, Monday, 22'nd Jan 2024
An analyst made a major change to his take on the biotech. He raised his price target considerably.
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 29.51%: Read This Before Placing a Bet
10:56am, Monday, 22'nd Jan 2024
The consensus price target hints at a 29.5% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
03:57pm, Tuesday, 16'th Jan 2024
For many biotech stocks, price and performance hinges on the success of a drug in testing. This means most biotech companies rely on one market opportunity to succeed financially.
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
02:17pm, Wednesday, 10'th Jan 2024
Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
11:43am, Wednesday, 10'th Jan 2024
The future of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy looked grim two months ago. There's been a 180 since.
5 Mid-Cap Stocks to Buy in a Volatile January
09:46am, Wednesday, 10'th Jan 2024
We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?
07:31am, Wednesday, 10'th Jan 2024
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near
Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
12:02pm, Tuesday, 09'th Jan 2024
Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
11:22am, Tuesday, 09'th Jan 2024
Sarepta Therapeutics (NASDAQ: SRPT ) stock is rising higher on Tuesday after positive comments were made by its CEO at the JPMorgan Healthcare Conference. Sarepta Therapeutics CEO Douglas Ingram said
